LKB1 modulates lung cancer differentiation and metastasis
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Germline mutation in serine/threonine kinase 11 (STK11, also called LKB1) results in Peutz-Jeghers syndrome, characterized by intestinal hamartomas and increased incidence of epithelial cancers. Although uncommon in most sporadic cancers, inactivating somatic mutations of LKB1 have been reported in primary human lung adenocarcinomas and derivative cell lines. Here we used a somatically activatable mutant Kras-driven model of mouse lung cancer to compare the role of Lkb1 to other tumour suppressors in lung cancer. Although Kras mutation cooperated with loss of p53 or Ink4a/Arf (also known as Cdkn2a) in this system, the strongest cooperation was seen with homozygous inactivation of Lkb1. Lkb1-deficient tumours demonstrated shorter latency, an expanded histological spectrum (adeno-, squamous and large-cell carcinoma) and more frequent metastasis compared to tumours lacking p53 or Ink4a/Arf. Pulmonary tumorigenesis was also accelerated by hemizygous inactivation of Lkb1. Consistent with these findings, inactivation of LKB1 was found in 34% and 19% of 144 analysed human lung adenocarcinomas and squamous cell carcinomas, respectively. Expression profiling in human lung cancer cell lines and mouse lung tumours identified a variety of metastasis-promoting genes, such as NEDD9, VEGFC and CD24, as targets of LKB1 repression in lung cancer. These studies establish LKB1 as a critical barrier to pulmonary tumorigenesis, controlling initiation, differentiation and metastasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Beyond its role regulating metabolism via AMPK, LKB1 loss promotes tumorigenesis by reprogramming epigenetic states, facilitating lineage plasticity and promoting metastasis22,67–70.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [22]
In the citing paper
“Somatic deletion of Lkb1 is insufficient for initiation of lung carcinogenesis in mice as a singular event but dramatically accelerates KrasG12D-driven carcinogenesis and fosters early metastatic dissemination84.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [84]
In the citing paper
“In addition, loss of Lkb1 results in epigenetic reprogramming and an expanded tumor histological repertoire, with high incidence of squamous or adenosquamous carcinomas, in agreement with data supporting enrichment of LKB1 mutations in human adenosquamous NSCLC84–86.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [84]
In the citing paper
“Loss of p53 or expression of either dominant negative or dominant gain-of-function Trp53 mutants also co-operate with oncogenic Kras to induce LUADs with shortened latency and increased metastatic proclivity, although these tumors are less aggressive than those with Lkb1 loss69–71, 84.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [84]
Citations
Cites
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Bolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,266
Summaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,887 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Identification of Pancreatic Cancer Stem Cells
Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., Wicha, M., Clarke, M. F., & Simeone, D. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2030 · Cited by 3,339
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Self-citationRole of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
Molecular Definition of Breast Tumor Heterogeneity
Shipitsin, M., Campbell, L. L., Argani, P., Weremowicz, S., Bloushtain-Qimron, N., Yao, J., Nikolskaya, T., Serebryiskaya, T., Beroukhim, R., Hu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.01.013 · Cited by 1,353
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Self-citationThe LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,077
Self-citation
Cited by
Items 501–600 of 1,000
Loss of the SWI/SNF ATPase subunits BRM and BRG1 drives lung cancer development
Marquez, S. B., Rai, S. K., Gramling, S. J. B., Lu, L., & Reisman, D. (2016) · Oncoscience · doi:10.18632/oncoscience.323 · Cited by 35
“combined Lkb1 inactivation with Kras activation and found that mice with the Kras Lkb1-/- phenotype developed metastases to intraparenchymal lung lymph nodes (equivalent to stage 2 human lung cancer) at a rate of 50-60%; however, fewer than 4% of mice developed distal metastases outside of the thoracic cavity [42].”
BackgroundEpithelial cell plasticity: breaking boundaries and changing landscapes
Tata, A., Chow, R. D.-W., & Tata, P. R. (2021) · EMBO Reports · doi:10.15252/embr.202051921 · Cited by 33
Discovery of Small Molecule Bak Activator for Lung Cancer Therapy
Park, D., Anisuzzaman, A. S. M., Magis, A. T., Chen, G., Xie, M., Zhang, G., Behera, M., Sica, G., Ramalingam, S. S., Owonikoko, T. K., et al. (2021) · Theranostics · doi:10.7150/thno.60349 · Cited by 35
“KL) mice were generated and bred out as previously described [30, 31, 50, 51].”
BackgroundMethodDecreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma
Yang, J., Jiang, S.-H., Liu, D., Yang, X., Huo, Y., Li, J., Hua, R., Zhang, Z., & Sun, Y. (2015) · Scientific Reports · doi:10.1038/srep10575 · Cited by 32
Dictyostelium, a microbial model for brain disease
Annesley, S. J., Chen, S., Francione, L. M., Sanislav, O., Chavan, A. J., Farah, C., Piazza, S. W. D., Storey, C., Ilievska, J., Fernando, S., et al. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.10.019 · Cited by 37
Wang, T., Abou–Ouf, H., Hegazy, S. A., Alshalalfa, M., Stoletov, K. V., Lewis, J. D., Donnelly, B. J., & Bismar, T. A. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1458-4 · Cited by 32
“, San Diego, CA) as described previously [19].”
Azam, S. H., Porrello, A., Harrison, E. B., Leslie, P. L., Liu, X., Waugh, T. A., Belanger, A., Mangala, L. S., Lopez‐Berestein, G., Wilson, H. L., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0786-6 · Cited by 34
Class IA Phosphatidylinositol 3-Kinase Signaling in Non-small Cell Lung Cancer
Solomon, B., & Pearson, R. B. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181a74dba · Cited by 33
Shackelford, D. B. (2013) · Journal of Carcinogenesis · doi:10.4103/1477-3163.116323 · Cited by 33
Salim, H., Arvanitis, A., Petris, L. D., Kanter, L., Hååg, P., Zovko, A., Özata, D. M., Lui, W., Lundholm, L., Zhivotovsky, B., et al. (2013) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22085 · Cited by 34
“…when it is combined with deficient expression of the tumor suppressor gene LKB1 or in combination with upregulation of oncogenes, for example, TBK1, c-Raf, NFjB, CDK4, and HIF2a (Ji et al., 2007; Barbie et al., 2009; Kim et al., 2009; Puyol et al., 2010; Blasco et al., 2011; Xue et al., 2011).”
BackgroundGenetically modified mouse models of cancer invasion and metastasis
Rampetsreiter, P., Casanova, E., & Eferl, R. (2011) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2011.05.003 · Cited by 32
“Adeno-Cre/KRAS/ LKB1 Lung LN, skeleton 61 Ji (2007) [32] http://www.”
Tumor suppressor interactions with microtubules: keeping cell polarity and cell division on track
Hernández, P., & Tirnauer, J. S. (2010) · Disease Models & Mechanisms · doi:10.1242/dmm.004507 · Cited by 32
“Somatic LKB1 mutations have been identified in a subset of sporadic nonsmall cell lung cancers, especially in male smokers, as well as in a variety of other sporadic tumors (Giardiello et al., 2000; Ji et al., 2007; Matsumoto et al., 2007).”
BackgroundKaufman, J. M., Yamada, T., Park, K., Timmers, C. D., Amann, J. M., & Carbone, D. P. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1639 · Cited by 31
Unraveling the Role of STK11/LKB1 in Non-small Cell Lung Cancer
Sumbly, V., & Landry, I. (2022) · Cureus · doi:10.7759/cureus.21078 · Cited by 39
“STK11/LKB1 mutations are more prevalent in lung adenocarcinomas but are also found in pulmonary squamous cell carcinoma and large cell adenocarcinoma [35].”
BackgroundLKB1 regulates TCR‐mediated PLCγ1 activation and thymocyte positive selection
Cao, Y., Li, H., Liu, H., Zhang, M., Hua, Z., Ji, H., & Liu, X. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.116 · Cited by 33
Self-citationYe, T., Pan, Y., Wang, R., Hu, H., Zhang, Y., Li, H., Wang, L., Sun, Y., & Chen, H. (2014) · PubMed Central · doi:10.3978/j.issn.2072-1439.2014.08.50 · Cited by 30
“On the other hand, mutations in tumor suppressor genes including TP53 and LKB1, which are also frequently seen in lung cancer, have been revealed to contribute to the pathogenesis of NSCLC as well (15-17).”
BackgroundLi, F., Fang, Z., Zhang, J., Li, C., Liu, H., Xia, J., Zhu, H., Guo, C., Qin, Z., Li, F., et al. (2016) · Cell Research · doi:10.1038/cr.2016.111 · Cited by 30
Self-citationSun, L., Liu, X., Fu, H., Zhou, W., & Zhong, D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168793 · Cited by 33
Faget, J., Contat, C., Zangger, N., Peters, S., & Meylan, E. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.11.121 · Cited by 33
Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma
Boiarsky, D., Lydon, C., Chambers, E. S., Sholl, L. M., Nishino, M., Skoulidis, F., Heymach, J. V., Luo, J., Awad, M. M., Janne, P. A., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.04.514 · Cited by 35
Squamous Non–small Cell Lung Cancer as a Distinct Clinical Entity
Oliver, T. G., Patel, J. C., & Akerley, W. (2013) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3182a0e850 · Cited by 29
“pathways could be exploited for the treatment of these tumors; however, the feasibility of this approach is currently unknown.(62) The transcription factor sex determining region Y-box 2 (SOX2) is amplified in a high percentage of squamous tumors, but therapeutic strategies to block SOX2 function and its critical targ…”
BackgroundRole of Genotyping in Non-Small Cell Lung Cancer Treatment: Current Status
Bonanno, L., Favaretto, A. G., Rugge, M., Tarón, M., & Rosell, R. (2011) · Drugs · doi:10.2165/11597700-000000000-00000 · Cited by 31
Liver kinase�B1 restoration promotes exosome secretion and motility of lung cancer cells
Zhang, C., Xiao, X., Chen, M., Aldharee, H., Chen, Y., & Long, W. (2017) · Oncology Reports · doi:10.3892/or.2017.6085 · Cited by 29
“While some studies have shown that LKB1 inhibits cancer cell migration and tumor metastasis (22-25), others have reported that LKB1 positively regulates the signaling of PAKs at the cell membrane region and stimulates the formation of protrusive membrane structures (lamellipodia) (26), suggesting a motility-stimulatin…”
BackgroundKim, H. I., Hong, S. H., Ku, J. M., Lim, Y. S., Lee, S. J., Song, J., Kim, T. Y., Cheon, C., & Ko, S. (2019) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x19500368 · Cited by 30
JNK1/2 represses Lkb1-deficiency-induced lung squamous cell carcinoma progression
Liu, J., Wang, T., Creighton, C. J., Wu, S., Ray, M., Janardhan, K. S., Willson, C. J., Cho, S.-N., Castro, P. D., Ittmann, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09843-1 · Cited by 33
AMPKα-like proteins as LKB1 downstream targets in cell physiology and cancer
Molina, E., Hong, L., & Chefetz, I. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02040-y · Cited by 32
Fan, T. T., Lu, Z., Liu, Y., Wang, L., Tian, H., Zheng, Y., Zheng, B. J., Xue, L., Tan, F., Xue, Q., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.665407 · Cited by 43
“The homozygous inactivation of LKB1 showed a strong cooperation with KRAS mutation in non-small cell lung cancer (NSCLC) (22).”
BackgroundLiu, X.-H., Qi, L., Alolga, R. N., & Liu, Q. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.66834 · Cited by 32
“Liver kinase B1 (LKB1) controls the initiation, differentiation and metastasis of lung cancer cells, and is a key barrier to the development and progression of lung cancer [39].”
BackgroundChen, X., Xie, C., Fan, X., Jiang, Z., Wong, V. K. W., Xu, J., Yao, X., Liu, L., & Leung, E. L. (2017) · Oncotarget · doi:10.18632/oncotarget.21716 · Cited by 29
“The essential role of AMPK has led to the development of numerous AMPK activators which might be used as novel drug candidates in the treatment of AMPK related disorders, diabetes, obesity, and other metabolic diseases, as well as cancer [5-9].”
BackgroundThe Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non–Small Cell Lung Cancer
Shukuya, T., Yamada, T., Koenig, M. J., Xu, J., Okimoto, T., Li, F., Amann, J. M., & Carbone, D. P. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.019 · Cited by 31
Li, H., Qi, W.-L., Wang, Y., & Meng, L. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.011 · Cited by 32
Adler, N., Bahcheli, A. T., Cheng, K., Al‐Zahrani, K. N., Slobodyanyuk, M., Pellegrina, D. V. D. S., Schramek, D., & Reimand, J. (2023) · Science Advances · doi:10.1126/sciadv.adh3083 · Cited by 33
EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation
Qin, Z., Yue, M., Tang, S., Wu, F., Sun, H., Li, Y., Zhang, Y., Izumi, H., Huang, H., Wang, W., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20232028 · Cited by 34
“IHC (immunohistochemistry) staining was performed as previously described (Ji et al., 2007).”
Self-citationOwonikoko, T. K., Ramalingam, S. S., Miller, D., Force, S. D., Sica, G., Sheldon, J. M., Chen, Z., Rogatko, A., Tighiouart, M., Harvey, R. D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1998 · Cited by 30
“The exquisite sensitivity of a patient with sarcomatoid NSCLC to a short duration of treatment with single-agent everolimus prompted the detailed characterization of the molecular and genetic phenotype of the tumor.”
BackgroundInfluentialA Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma
Chen, L., Engel, B. E., Welsh, E. A., Yoder, S., Brantley, S. G., Chen, D., Beg, A. A., Cao, C., Kaye, F. J., Haura, E. B., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.02.009 · Cited by 29
Self-citationBlake, D. C., Mikse, O. R., Freeman, W. M., & Herzog, C. R. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.03.013 · Cited by 31
Molecular Pathology of Lung Cancer
Solis, L. M., & Wistuba, I. I. (2012) · Springer eBooks · doi:10.1007/978-1-4419-0787-5_14 · Cited by 27
Genome-wide DNA methylation analysis of KRAS mutant cell lines
Tew, B. Y., Durand, J. K., Bryant, K. L., Hayes, T. K., Peng, S., Tran, N. L., Gooden, G. C., Buckley, D. N., Der, C. J., Baldwin, A. S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-66797-x · Cited by 29
Targeting HSPA1A in ARID2-deficient lung adenocarcinoma
Wang, X., Wang, Y., Fang, Z., Wang, H., Zhang, J., Zhang, L., Huang, H., Jiang, Z., Jin, Y., Han, X., et al. (2021) · National Science Review · doi:10.1093/nsr/nwab014 · Cited by 29
Self-citationHistologic transformation in lung cancer: when one door shuts, another opens
Sato, Y., Saito, G., & Fujimoto, D. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221130503 · Cited by 27
Kim, W. Y., & Sharpless, N. E. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2011_160 · Cited by 30
“To shorten tumor latency, such systems often also include deletion of relevant tumor suppressor genes (e.g. p16Ink4a, p53, Pten) in the same tissues (see for example Ji et al. 2007).”
BackgroundSelf-citationSystems biology approaches to develop innovative strategies for lung cancer therapy
Viktorsson, K., Lewensohn, R., & Zhivotovsky, B. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.28 · Cited by 27
“The metastasis-associated gene signature showed significant overlap with profiles observed in clinical specimens containing both Kras and Lkb1 alterations.(30) Examination of the tyrosine phosphoproteome of the Lkb1 deleted LC cells by MS analysis showed a critical role for Src activation, as the”
ResultZhang, L., Wang, J.-C., Hou, L., Cao, P.-R., Wu, L., Zhang, Q., Yang, H., Zang, Y., Ding, J., & Li, J. X. (2015) · Scientific Reports · doi:10.1038/srep10115 · Cited by 33
“The loss-of-function of LKB1 has been particularly well studied in lung cancer 24–28 .”
Ohashi, K., Takigawa, N., Osawa, M., Ichihara, E., Takeda, H., Kubo, T., Hirano, S., Yoshino, T., Takata, M., Tanimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4205 · Cited by 31
“These observations suggest that activating EGFR mutations play a critical role in tumorigenesis, although further genetic alterations were needed to obtain the fully malignant phenotype (34).”
BackgroundMapping lung squamous cell carcinoma pathogenesis through in vitro and in vivo models
Gómez‐López, S., Whiteman, Z. E., & Janes, S. M. (2021) · Communications Biology · doi:10.1038/s42003-021-02470-x · Cited by 27
Wang, P., Yang, W. Z., Guo, H., Dong, H., Guo, Y., Gan, H., Wang, Z., Cheng, Y., Deng, Y., Xie, S.-Z., et al. (2021) · Advanced Science · doi:10.1002/advs.202101501 · Cited by 36
Enhanced antitumor effect of cisplatin in human NSCLC cells by tumor suppressor LKB1
Ou, W., Ye, S., Yang, W., Wang, Y., Ma, Q., Yu, C., Shi, H., Yuan, Z., Zhong, G., Ren, J., et al. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2012.18 · Cited by 26
Tan, X., Carretero, J., Chen, Z., Zhang, J., Wang, Y., Chen, J., Li, X., Ye, H., Tang, C., Cheng, X., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080885 · Cited by 30
“KrasG12D activation accompanied by p53 deletion can cause lung tumor metastasis [37], therefore, KrasG12D; p53flox/flox; IL-6-/- mice were generated to investigate the influence of IL-6 deletion on lung cancer metastasis.”
BackgroundSelf-citationLKB1 loss of function studied in vivo
Shorning, B. Y., & Clarke, A. R. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.01.019 · Cited by 27
“effect than concomitant mutations of K-Ras with other tumour suppressors such as p53, Ink4a/Arf or p16 [57].”
BackgroundColby, S., Yehia, L., Niazi, F., Chen, J.-L., Ni, Y., Mester, J. L., & Eng, C. (2016) · Molecular Case Studies · doi:10.1101/mcs.a001230 · Cited by 26
“However, this is paralleled by the discovery of somaticinactivating mutations of LKB1 (also known as STK11, encoding serine/threonine kinase 11) in lung adenocarcinomas and squamous cell carcinomas (Ji et al. 2007).”
BackgroundLKB1: Can We Target an Hidden Target? Focus on NSCLC
Ndembe, G., Intini, I., Perin, E., Marabese, M., Caiola, E., Mendogni, P., Rosso, L., Broggini, M., & Colombo, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.889826 · Cited by 34
“org 7 Targeting LKB1 to Prevent Metastasis LKB1 plays an important role also in metastasis (8).”
BackgroundEntrialgo‐Cadierno, R., Cueto‐Ureña, C., Welch, C., Feliu, I., Macaya, I., Vera, L., Morales, X., Michelina, S. V., Scaparone, P., López, I., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01788-w · Cited by 28
“Mut KRAS LUAD harbouring inactivating LKB1 mutations display poor prognosis, in part due to an enhanced metastatic potential [41, 42].”
AMPK Control of mTOR Signaling and Growth
Gwinn, D. M., & Shaw, R. J. (2010) · The Enzymes · doi:10.1016/s1874-6047(10)28003-4 · Cited by 33
Linher‐Melville, K., & Singh, G. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-415 · Cited by 28
“Acting either as a kinase or by changing its subcellular localization, LKB1 has been associated with proliferation, cell cycle arrest, apoptosis, polarity/motility, and energy metabolism (reviewed in [21]), and has been described as a tumor suppressor during pulmonary tumorigenesis [22].”
BackgroundLiang, X., WANG, P., Gao, Q., & Tao, X. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.1916 · Cited by 25
LKB1 inactivation sensitizes non-small cell lung cancer to pharmacological aggravation of ER stress
Inge, L. J., Friel, J. M., Richer, A. L., Fowler, A. J., Whitsett, T. G., Smith, M. A., Tran, N. L., & Bremner, R. M. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.06.011 · Cited by 27
Keratin 14-high subpopulation mediates lung cancer metastasis potentially through Gkn1 upregulation
Yao, S., Huang, H., Han, X., Ye, Y., Qin, Z., Zhao, G., Li, F., Hu, G., Hu, L., & Ji, H. (2019) · Oncogene · doi:10.1038/s41388-019-0889-0 · Cited by 26
Self-citationJiang, L., Liang, X., Liu, M., Wang, W., Ma, J., Guo, Q., HAN, L., Yang, C., & Nan, K. (2014) · Oncology Reports · doi:10.3892/or.2014.3432 · Cited by 24
“Ji et al (11) provided strong evidence that LKB1 plays a key role in lung cancer differentiation and metastasis.”
BackgroundHe, T.-Y., Tsai, L., Huang, C., Chou, M., & Lee, H. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3824-1 · Cited by 24
Dissecting the role of polarity regulators in cancer through the use of mouse models
Gödde, N., Pearson, H. B., Smith, L. K., & Humbert, P. O. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.08.036 · Cited by 27
Potential Molecular Signatures Predictive of Lung Cancer Brain Metastasis
Pedrosa, R. M. S. M., Mustafa, D. A. M., Aerts, J. G. J. V., & Kros, J. M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00159 · Cited by 24
“Animal models have given clear evidence that LKB1 haploinsufficiency stimulates KRAS driven lung cancer in mice (81), and a single copy inactivation of LKB1 can considerably ease brain recurrence (82).”
BackgroundMetabolic signatures of four major histological types of lung cancer cells
Lim, S. L., Jia, Z., Lu, Y., Zhang, H., Ng, C.-T., Bay, B., Shen, H., & Ong, C. N. (2018) · Metabolomics · doi:10.1007/s11306-018-1417-x · Cited by 24
“Lung cancers are generally classified as either non-small cell lung carcinoma (NSCLC) or small cell lung carcinoma (SCLC), which constitute of approximately 85 and 15%, respectively.”
BackgroundInfluentialFaulty Epithelial Polarity Genes and Cancer
Tervonen, T. A., Partanen, J. I., Saarikoski, S. T., Myllynen, M., Marques, E., Paasonen, K., Moilanen, A., Wohlfahrt, G., Kovanen, P. E., & Klefström, J. T. (2011) · Advances in cancer research · doi:10.1016/b978-0-12-385524-4.00003-9 · Cited by 27
Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures
Satpathy, S., Clark, N. M., Chen, Y., Hosseini, N., Chang, Y.-H., Hsiao, Y., Lei, J. T., Petralia, F., Chen, J., Geffen, Y., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.07.011 · Cited by 32
Ren, T., Tang, Y., Wang, M., Wang, H., Liu, Y., Qian, X., Chang, C., & Chen, M. (2020) · Oncology Reports · doi:10.3892/or.2020.7763 · Cited by 23
In vivo miRNA knockout screening identifies miR-190b as a novel tumor suppressor
Hong, H., Yao, S., Zhang, Y., Ye, Y., Li, C., Hu, L., Sun, Y., Huang, H., & Ji, H. (2020) · PLoS Genetics · doi:10.1371/journal.pgen.1009168 · Cited by 37
“H&E was performed as previously described [48].”
Self-citationJin, R., Liu, B., Liu, X., Fan, Y., Peng, W., Huang, C., Marcus, A. I., Sica, G., Gilbert‐Ross, M., Liu, Y., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0567 · Cited by 24
“In addition, it was not possible to isolate cancer cell lines with only Kras and LKB1 mutations, and the functional studies were done with cell lines containing Kras, LKB1, and TP53 triple mutation (37).”
BackgroundNedd9 Restrains Autophagy to Limit Growth of Early Stage Non–Small Cell Lung Cancer
Deneka, A. Y., Kopp, M. C., Nikonova, A. S., Gaponova, A. V., Kiseleva, A. A., Hensley, H. H., Flieder, D. B., Serebriiskii, I. G., & Golemis, E. A. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3626 · Cited by 26
“Loss of Lkb1 inducesNedd9, in a process that promotesmetastasis (14).”
BackgroundTET2–STAT3–CXCL5 nexus promotes neutrophil lipid transfer to fuel lung adeno-to-squamous transition
Xue, Y., Chen, Y., Sun, S., Tong, X., Chen, Y., Tang, S., Wang, X., Bi, S., Qiu, Y., Zhao, Q., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20240111 · Cited by 31
Self-citationRole of NEDD9 in invasion and metastasis of lung adenocarcinoma
Chang, J., Gao, F., Zhao, G., & Zhang, G. (2012) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2012.693 · Cited by 23
“In human lung adenocarcinoma, NEDD9 expression is upregulated upon loss of the tumor suppressor serine/threonine kinase 11 (STK11, also called LKB1), and its expression is downregulation upon re-expression of LKB1 (17).”
Stražišar, M., Mlakar, V., Rott, T., & Glavač, D. (2009) · Cancer Investigation · doi:10.1080/07357900802427919 · Cited by 23
“Based on human lung cancer cell lines studies and LKB1- deficient mouse, it was proposed that LKB1 might represent a critical barrier to pulmonary tumourigenesis (8).”
BackgroundInfluentialPresneau, N., Duhamel, L. A., Ye, H., Tirabosco, R., Flanagan, A. M., & Eskandarpour, M. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.174 · Cited by 23
Närhi, K. M., Nagaraj, A. S., Parri, E., Turkki, R., van Duijn, P. W., Hemmes, A., Lahtela, J., Uotinen, V., Mäyränpää, M. I., Salmenkivi, K., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5059 · Cited by 25
“In contrast, Kras;Lkb1 (KL) mice develop more aggressive tumours with an expanded histopathology spectrum [14,16], and we recently showed that histotype spectra are dependent on the cell of origin: whereas alveolar progenitors predominantly lead to the formation of papillary AC, bronchiolar progenitors predominantly l…”
BackgroundTyping tumors using pathways selected by somatic evolution
Wang, S., Ma, J., Zhang, W., Shen, J. P., Huang, J. K.-L., Peng, J., & Ideker, T. (2018) · Nature Communications · doi:10.1038/s41467-018-06464-y · Cited by 25
A Phase I Study of Temsirolimus and Thoracic Radiation in Non–Small-Cell Lung Cancer
Waqar, S. N., Robinson, C. G., Bradley, J. D., Goodgame, B. W., Rooney, M., Williams, K., Gao, F., & Govindan, R. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.11.007 · Cited by 25
Inge, L. J., Coon, K. D., Smith, M. A., & Bremner, R. M. (2009) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2008.11.029 · Cited by 23
Synergistic Effect of Phenformin in Non-Small Cell Lung Cancer (NSCLC) Ionizing Radiation Treatment
Wang, J., Xia, S., & Zhu, Z. (2014) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-0283-z · Cited by 25
“normal LKB1 [15, 16].”
Ghosh, M., Dwyer‐Nield, L. D., Kwon, J. B., Barthel, L., Janssen, W. J., Merrick, D. T., & Keith, R. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122823 · Cited by 23
“There are three established murine models of lung SCC: 1) topical treatment with N-nitroso tris chloroethylurea (NTCU) [6–9]; 2) inactivation of tumor suppressor LKB1 [10]; and 3) downregulation of IKKα [11].”
BackgroundPreclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development
Estape, A. A., Foggetti, G., Starrett, J. H., Nguyen, D. X., & Politi, K. A. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037820 · Cited by 23
LKB1 drives stasis and C/EBP-mediated reprogramming to an alveolar type II fate in lung cancer
Murray, C. W., Brady, J. J., Han, M., Cai, H., Tsai, M. K., Pierce, S. E., Cheng, R., Demeter, J., Feldser, D. M., Jackson, P. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28619-8 · Cited by 22
DuCote, T. J., Naughton, K. J., Skaggs, E. M., Bocklage, T. J., Allison, D. B., & Brainson, C. F. (2023) · Laboratory Investigation · doi:10.1016/j.labinv.2023.100176 · Cited by 24
Molecular changes in smoking-related lung cancer
Begum, S. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.11.84 · Cited by 23
Liao, S., Liang, L., Yue, C., He, J., He, Z., Jin, X., Luo, G., & Zhou, Y. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5040 · Cited by 31
“It has been proposed that oncogene expression is sufficient to reprogram certain aspects of nutrient utilization, suggesting that cell-autonomous metabolism is driven in part by oncogenes (20,45,46).”
BackgroundWang, Y., Rouggly, L. C., You, M., & Lubet, R. A. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-394596-9.00007-x · Cited by 22
LKB1 suppresses proliferation and invasion of prostate cancer through hedgehog signaling pathway.
Xu, P., Cai, F., Liu, X., & Guo, L. (2014) · Europe PMC (PubMed Central) · Cited by 23
Role of PTEN in basal cell derived lung carcinogenesis
Malkoski, S. P., Cleaver, T. G., Thompson, J. J., Sutton, W., Haeger, S. M., Rodriguez, K. J., Lu, S., Merrick, D., & Wang, X. (2013) · Molecular Carcinogenesis · doi:10.1002/mc.22030 · Cited by 22
“Genetic NSCLC mouse models produce mainly adenomas and AdCs [9], although some models also produce a limited number of SCCs [10,11].”
BackgroundMethodVARMUS, H. E., Unni, A. M., & Lockwood, W. W. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030866 · Cited by 22
The role of STK11/LKB1 in cancer biology: implications for ovarian tumorigenesis and progression
Kang, J., Gallucci, S., Pan, J., Oakhill, J. S., & Sanij, E. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1449543 · Cited by 24
“…which genetic manipulation of Lkb1 in mouse tissues did not promote prostate cancer (Hermanova et al., 2020), bladder cancer (Shorning et al., 2011), serous ovarian cancer (Tanwar et al., 2014), lung cancer (Ji et al., 2007), melanoma (Liu et al., 2012) or endometrial cancer (Cheng et al., 2014).”
The expression of stem cell‐related indicators as a prognostic factor in human lung adenocarcinoma
Zhang, X., Dong, Q., Huang, J., Huang, A., Shi, C., Jin, B., Sha, H., Feng, J., Qin, G., Zhou, J., et al. (2010) · Journal of Surgical Oncology · doi:10.1002/jso.21718 · Cited by 21
“[37] reported that lung adenocarcinoma initiated by K-ras oncogene was not metastatic, and additional inactivation of tumor suppressor genes, such as LKB1 (also called STK11), was required for metastasis.”
BackgroundBeyond ENO1, emerging roles and targeting strategies of other enolases in cancers
Ni, J., Huang, Y., Li, C., Yin, Q., & Ying, J. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.100750 · Cited by 24
O’Neill, E. J., Sze, S. K., MacPherson, R. E. K., & Tsiani, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25041950 · Cited by 21
“Liver kinase B1 (LKB1) is a tumor suppressor and upstream kinase of the AMPK pathway that is mutated in 39% of NSCLC cell lines and 34% of human lung adenocarcinoma specimens [26–28].”
BackgroundLocalization‐specific LKB1 loss in head and neck squamous cell carcinoma metastasis
Kline, E. R., Müller, S., Pan, L., Tighiouart, M., Chen, Z. (., & Marcus, A. I. (2010) · Head & Neck · doi:10.1002/hed.21638 · Cited by 22
Do CDK4/6 inhibitors have potential as targeted therapeutics for squamous cell cancers?
Kalu, N. N., & Johnson, F. M. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1274731 · Cited by 24
“These lung SCC mouse models were established chemically and by simultaneous activation of KrasG12D and inactivation of Lkb1 [83,84].”
BackgroundPotential Molecular Targets in the Treatment of Lung Cancer Using siRNA Technology
Zarredar, H., Ansarin, K., Baradaran, B., Khosroshahi, S. A., & Farajnia, S. (2018) · Cancer Investigation · doi:10.1080/07357907.2017.1416393 · Cited by 23
“EGFR (epidermal growth factor receptor) is a member of ErbB family that consists of four members including HER-1/ErbB1, HER2/neu/ ErbB2, HER3/ErbB3, and HER4/ErbB4 receptor tyrosine kinases (18).”
BackgroundDiagnostic and Predictive Immunohistochemistry for Non–Small Cell Lung Carcinomas
Hung, Y. P., & Sholl, L. M. (2018) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000206 · Cited by 23
FOXM1c promotes oesophageal cancer metastasis by transcriptionally regulating IRF1 expression
Zhou, Y., Wang, Q., Chu, L., Dai, W., Zhang, X., Chen, J., Zhang, L., Ding, P., Zhang, X., Gu, H., et al. (2018) · Cell Proliferation · doi:10.1111/cpr.12553 · Cited by 22
Self-citationMetabolic Potential of Cancer Cells in Context of the Metastatic Cascade
Benzarti, M., Delbrouck, C., Neises, L., Kiweler, N., & Meiser, J. (2020) · Cells · doi:10.3390/cells9092035 · Cited by 23
“Other common mutations are found in the AMPK-activating kinase LKB1 [95], which downregulates the tumour suppressive effects of AMPK.”
BackgroundMazzaschi, G., Leonetti, A., Minari, R., Gnetti, L., Quaini, F., Tiseo, M., & Facchinetti, F. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00891-8 · Cited by 25
Targeting PGM3 as a Novel Therapeutic Strategy in KRAS/LKB1 Co-Mutant Lung Cancer
Lee, H., Cai, F., Kelekar, N., Velupally, N., & Kim, J. (2022) · Cells · doi:10.3390/cells11010176 · Cited by 23
“Consistent with previous studies [29], KL co-mutant cells generated bigger tumors compared to K mutant cells.”
ResultMoreau, D., Jacquot, C., Tsita, P., Chinou, İ., Tomasoni, C., Jugé, M., Antoniadou‐Vyza, E., Martignat, L., Pineau, A., & Roussakis, C. (2008) · International Journal of Cancer · doi:10.1002/ijc.23809 · Cited by 21
Metadata
- Authors
- Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., Liang, M.-C., Cai, D., Naumov, G. N., Bao, L., Contreras, C. M., Li, D., Chen, L., Krishnamurthy, J., Koivunen, J., Chirieac, L. R., Padera, R. F., Bronson, R. T., Lindeman, N. I., Christiani, D. C., Lin, X., Shapiro, G. I., Jänne, P. A., Johnson, B. E., Meyerson, M., Kwiatkowski, D. J., Castrillon, D. H., Bardeesy, N., Sharpless, N. E., & Wong, K.-K.
- Affiliations
- Dana-Farber Cancer Institute (US)
- University of North Carolina at Chapel Hill (US)
- Harvard University (US)
- University of Tennessee Health Science Center (US)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Brigham and Women's Hospital (US)
- Broad Institute (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Bardeesy, Nabeel
- Sharpless, Norman E.
- Wong, Kwok-Kin
- ORCID
- Ji, Hongbin
- Ramsey, Matthew R.
- Hayes, D. Neil
- Wu, Michael C.
- Shimamura, Takeshi
- Perera, Samanthi A.
- Liang, Mei-Chih
- Bao, Lei
- Chen, Liang
- Koivunen, Jussi
- Chirieac, Lucian R.
- Padera, Robert F.
- Bronson, Roderick T.
- Lindeman, Neal I.
- Christiani, David C.
- Lin, Xihong
- Shapiro, Geoffrey I.
- Johnson, Bruce E.
- Meyerson, Matthew
- Kwiatkowski, David J.
- Bardeesy, Nabeel
- Sharpless, Norman E.
- Wong, Kwok-Kin
- Venue
- Nature
- Published
- 2007-08-05
- Volume
- 448
- Issue
- 7155
- Pages
- 807-810
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2134964552
- Cited by
- 1,064
- References
- 36
- Citations by year
- 2026: 30 · 2025: 43 · 2024: 44 · 2023: 66 · 2022: 50 · 2021: 71 · 2020: 51 · 2019: 66 · 2018: 61 · 2017: 56 · 2016: 54 · 2015: 72 · 2014: 83 · 2013: 65 · 2012: 52
- FWCI
- 24.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- LKB1, STK11, lung cancer, tumour suppressor, metastasis, squamous cell carcinoma, non-small cell lung cancer, KRAS, p53, Ink4a/Arf, CDKN2A, tumor differentiation, Peutz-Jeghers syndrome, metastasis-promoting genes
- MeSH terms
- AMP-Activated Protein Kinase Kinases, Animals, Carcinoma, Non-Small-Cell Lung, Cell Differentiation, Disease Models, Animal, Humans, Lung Neoplasms, Neoplasm Metastasis, Genes, ras, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Genes, p53, Protein Serine-Threonine Kinases, Genes, p16, Gene Expression Profiling, Cell Line, Tumor, Mice, Genes, Neoplasm, AMP-Activated Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.